Optimising batch selection to increase success of PK studies for bioequivalence
Uncover Nanopharm’s SmartTrack approach for successful Pharmacokinetic and Bioequivalence studies in OINDP, using PBPK modelling.
Alternative Regulatory Pathway for Generic Inhaled Drugs
Uncover the pathways for generic OINDP and the challenges and solutions in the pharmaceutical regulatory landscape for inhalation drug products.
Physiologically-based Pharmacokinetic Models (PBPK) for OINDPs
Aptar Pharma discusses Physiologically based PK models for OINDPs.
Nanopharm’s SmartTrack: Accelerating OINDP Respiratory Drug Delivery
Revolutionize your OINDP respiratory drug delivery with Nanopharm’s SmartTrack. Accelerate development and mitigate risks through expert formulation and integrated solutions. Your pathway to success starts here.
Nanopharm’s Role in OINDP Bioequivalence & Pharmacokinetics
Explore Nanopharm’s groundbreaking methods in OINDP bioequivalence and pharmacokinetics. Learn how in vitro and in vivo studies are revolutionizing drug development and solubility.
Nanopharm: cGMP Drug Development in OINDP
Nanopharm expands with cGMP facilities for advanced drug development in OINDP. Specializing in biologics characterization and particle engineering.
Nanopharm & Leyden – OINDP Intranasal Sprays vs. Respiratory Viruses
Nanopharm & Leyden Labs collaborate on intranasal sprays for broad protection against respiratory viruses. Focused on OINDP drug development.
Challenging the Bioequivalence Hurdles for OINDPs: Achieving Q3 Structural Equivalence
Explore challenges in OINDP drug development, focusing on achieving bioequivalence in generic nasal formulations.
Advanced microscopy techniques to assess solid-state properties of inhalation medicines
Unveil Nanopharm’s expertise in advanced microscopy for OINDP. Explore solid-state analysis and its impact on inhalation medicines, including dry powder inhalers.
